Clincosm LogoSign in Get a demo

SeroPrevHUS: Seroprevalence of Covid-19 in the Staff of the University Hospitals of Strasbourg

Sponsor
University Hospital, Strasbourg, France (Other)
Overall Status
Recruiting
CT.gov ID
NCT05652582
Collaborator
(none)
5,694
Enrollment
1
Location
18.2
Anticipated Duration (Months)
312.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The Grand Est region is one of the most affected regions in France during the first wave of the COVID-19 epidemic. A significant increase in the number of patients hospitalized for SARS-CoV 2 infection at the University Hospitals of Strasbourg (HUS) led to a sudden saturation of their capacities. Hospital workers appear to be a population at particular risk for this new infectious agent. The percentage of hospital workers who have been in contact with the virus or have contracted COVID-19 is unknown.

The objective of this work is to determine the prevalence of SARS-CoV-2 positive serologies among hospital staff screened from June 22, 2020 to November 1, 2020 following a screening campaign offering serological testing to all volunteer HUS professionals.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    5694 participants
    Observational Model:
    Case-Only
    Time Perspective:
    Retrospective
    Official Title:
    Seroprevalence of SARS-CoV 2 in the Staff of the University Hospitals of Strasbourg
    Actual Study Start Date :
    Jun 24, 2021
    Anticipated Primary Completion Date :
    Dec 1, 2022
    Anticipated Study Completion Date :
    Dec 31, 2022

    Outcome Measures

    Primary Outcome Measures

    1. To determine the positive seroprevalence of SARS-CoV-2 among hospital staff screened from June 22, 2020 to November 1, 2020 [Files analysed retrospectively from June 22, 2020 to November 1, 2020 will be examined]

      Seroprevalence will be estimated by calculating the rate of seropositive subjects with its 95% confidence interval

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Inclusion criteria:

    • Adult subject (≥ 18 years of age)

    • Hospital staff practicing at HUS who performed SARS-CoV 2 serology in the period from 06/22/2020 to 11/1/2020

    Exclusion criteria:
    • Subject not meeting inclusion criteria

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Service Laboratoire de Virologie - PTM - CHU de Strasbourg - France Strasbourg France 67091

    Sponsors and Collaborators

    • University Hospital, Strasbourg, France

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    University Hospital, Strasbourg, France
    ClinicalTrials.gov Identifier:
    NCT05652582
    Other Study ID Numbers:
    • 8253
    First Posted:
    Dec 15, 2022
    Last Update Posted:
    Dec 15, 2022
    Last Verified:
    Dec 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital, Strasbourg, France
    COVID-19
    SARS-COV-2
    Prevalence of SARS-CoV-2
    Additional relevant MeSH terms:
    COVID-19

    Study Results

    No Results Posted as of Dec 15, 2022